CBD and pain: what French law allows you to say

No therapeutic claim has been recognised by the ANSM, the HAS, ANSES or the EFSA for wellness CBD. Stating that a product "relieves", "treats" or "cures" pain exposes the seller to the product being reclassified as a medicine by presentation, within the meaning of article L.5111-1 of the French Public Health Code, and to penalties from the DGCCRF for misleading commercial practice. This rule applies whatever the product format: oil, topical cosmetic or capsule.

Brands may use terms such as "joint comfort", "muscle relaxation" or "wellbeing ritual", provided they never link those phrases to a promise of a clinical result. For a cosmetic, that vocabulary must also remain consistent with European Cosmetics Regulation 1223/2009, which governs the claims authorised on the label and in commercial communication. Our article on day-to-day joint comfort rituals sets out examples of compliant wording.

Despite the absence of any authorised claim, some consumers report adding a CBD cosmetic to a massage ritual after intense physical activity or a tiring day. Such feedback remains a matter of personal preference, not clinically validated, and in no way constitutes proof of efficacy. No serious brand may present these testimonials as a guarantee of results.

Clinical trials looking specifically at CBD and the perception of pain remain few in number and are often limited by their sample sizes. This lack of robust data largely explains the cautious position of the French and European health authorities, which prefer not to validate any claim until a sufficient level of evidence has been established.

Rather than looking for a promise of an effect, it is better to check the product's certificate of analysis, its actual CBD content, and the measured THC level, which must remain at or below 0.30% in the finished product, in accordance with the Conseil d'État decision of 29 December 2022. These objective elements say far more about the quality of a product than any marketing phrase.

CBD is not a medicine. In cases of persistent pain, consult a healthcare professional rather than relying on a wellness product.

Can a brand say that its CBD product "relieves" pain?

No. That wording is a therapeutic claim, prohibited for a product without medicinal status, and penalised by the DGCCRF if it is used.

What vocabulary can a brand legally use?

Terms of comfort or wellbeing, such as "joint comfort" or "muscle relaxation", never promising a clinical or therapeutic result.

Are there serious studies on CBD and pain?

Clinical trials do exist, but they remain few in number and often limited in sample size, which explains the caution of the French health authorities.

How can you recognise a serious CBD product without misleading claims?

By checking its certificate of analysis, its actual CBD content and its measured THC level, rather than relying on a promised effect printed on the packaging.